Latham & Watkins Advises Goldman Sachs and Owl Rock in US$275 Million Financing for QuVa Pharma

Interdisciplinary team advised on the financing for the 503B outsourcing services company to healthcare facilities.

May 11, 2021

QuVa Pharma, Inc., the leading national 503B outsourcing services company providing hospitals with essential medications in ready-to-administer injectable formats, has announced its latest financing, a US$275 million senior debt facility led by investment vehicles managed by the Goldman Sachs Private Credit Investing, with participation from Owl Rock Capital Partners, LP. The financing enables QuVa Pharma to meet the needs of its approximately 2,000 hospital customers, add more hospitals to the platform, and expand its 200 SKU product portfolio.

Latham & Watkins LLP represented Goldman Sachs and Owl Rock in the financing with a team led by New York partners Stelios Saffos and Peter Sluka, with Houston counsel Bryce Kaufman and Houston associate Brian Flynn. Advice was also provided on tax matters by New York partner Jiyeon Lee-Lim and Houston partner Bryant Lee, with Houston associate Dominick Constantino; on FDA regulatory matters by Washington, D.C. associate Eitan Bernstein; and on environmental matters by Los Angeles/Washington, D.C. counsel Joshua Marnitz.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.